Strategies for Initiating Combination Antiretroviral Therapy

Michael L.#Tapper; Eric S.#Daar; Peter J.#Piliero; Kimberly#Smith; Corklin#Steinhart
April 2005
AIDS Patient Care & STDs;Apr2005, Vol. 19 Issue 4, p224
Academic Journal
Numerous potent antiretroviral regimens have proven successful as initial therapy in treat- ment-naïve HIV-infected patients. As the development of new agents makes possible new treatment regimens, providers are faced with increasingly complex questions of when to initiate treatment and which regimen to select for individual patients. Clinical trial data provide a foundation for choosing an initial regimen and play a key role in the formation of treatment guidelines issued by the United States Public Health Service and other organizations. This paper reviews the results of recent clinical trials focusing on initial therapy and addresses important considerations when beginning antiretroviral therapy (ART) in treatment-naïve individuals.


Related Articles

  • Research on interferon: a review. Tyrrell, D. A. J. // Journal of the Royal Society of Medicine;Feb1981, Vol. 74 Issue 2, p145 

    The article offers information about interferon. According to the research, interferon was discovered in 1957 after years of studying the virus interference. After its discovery, it was then initially suggested that interferon might be used as an antiviral drug. However, it was soon revealed...

  • TREATMENT BRIEFS.  // HIV Australia;2007, Vol. 7 Issue 1, p41 

    The article focuses on two international clinical trials of the drug interleukin-2 (IL-2, Proleukin) in Human Immunodeficiency Virus (HIV) afflicted people which had produced no result. IL-2 is reportedly a natural substance produced by T-cells that stimulates the production of CD4 T-cells. The...

  • HDAC inhibitors in HIV. Wightman, Fiona; Ellenberg, Paula; Churchill, Melissa; Lewin, Sharon R // Immunology & Cell Biology;Jan2012, Vol. 90 Issue 1, p47 

    Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from...

  • Translating Efficacy into Effectiveness in Antiretroviral Therapy. Fletcher, Courtney V. // Drugs;2007, Vol. 67 Issue 14, p1969 

    Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The...

  • Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV-1 Vaccine Candidates. Spentzou, Aggeliki; Bergin, Philip; Gill, Dilbinder; Cheeseman, Hannah; Ashraf, Ambreen; Kaltsidis, Harry; Cashin-Cox, Michelle; Anjarwalla, Insiyah; Steel, Alan; Higgs, Christopher; Pozniak, Anton; Piechocka-Trocha, Alicja; Wong, Johnson; Anzala, Omu; Karita, Etienne; Dally, Len; Gotch, Frances; Walker, Bruce; Gilmour, Jill; Hayes, Peter // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p720 

    We have characterized an assay measuring CD8 T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of primary HIV- 1 isolates. The assay uses relatively simple autologous cell culture and...

  • CD4+ Cell Count Increase Predicts Clinical Benefits in Patients with Advanced HIV Disease and Persistent Viremia after 1 Year of Combination Antiretroviral Therapy. Loutfy, Mona R.; Walmsley, Sharon L.; Mullin, Christopher M.; Perez, George; Neaton, James D. // Journal of Infectious Diseases;10/15/2005, Vol. 192 Issue 8, p1407 

    The relationship between 12-month CD4+ cell count response and clinical outcome (AIDS-defining event or death) in a subset of 228 patients with a human immunodeficiency virus load >400 copies/mL despite receiving combination antiretroviral therapy as part of a larger randomized trial was defined...

  • Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Conant, M. A.; Schacker, T. W.; Murphy, R. L.; Gold, J.; Crutchfield, L. T.; Crooks, R. J.; International Valaciclovir HSV Study Group // International Journal of STD & AIDS;Jan2002, Vol. 13 Issue 1, p12 

    Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ > or = 100 cells/mm(3)) received suppressive valaciclovir or aciclovir...

  • Resistance study to re-evaluate HAART. Kenyon, Georgina // Nature Medicine;May2001, Vol. 7 Issue 5, p515 

    Reports on the international trial to determine the effectiveness of the treatment for AIDS patients for failure of triple therapy on them. Development of HIV resistance to antiretroviral therapy (HAART); Increase in the global management of drug regime; Evaluation of the benefits for the...

  • Predicting Success. Allen, I. Elaine; Seaman, Christopher A. // Quality Progress;Feb2009, Vol. 42 Issue 2, p60 

    The article discusses the simulation in drug development to predict potential success in clinical trials. It notes that knowing the probable success of specific patient population can cut costs or halt a trial before investing large amounts on the trials. Moreover, the interim futility...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics